The FDA is now requiring other manufacturers
of long-acting generic
formulations of Wellbutrin XL 300 (bupropion
) to conduct their own bioequivalence trials. Here is what the FDA has required:
"FDA recently asked each of the other manufacturers - Anchen, Actavis, Watson, and Mylan - to conduct their own studies to assess the bioequivalence of their 300 mg extended-release bupropion tablets to Wellbutrin XL 300 mg.